Saol Therapeutics competitors

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.

Christopher J. Schaber, PhD has over 30 years experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been Soligenix's President and Chief Executive Officer and a director since August 2006. He also served on the board of directors for the Alliance for BioSecurity and for the Biotechnology Council of NJ (BioNJ), where he is currently Chair. He has been a member of the corporate councils for both the National Organization for Rare Disorders (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT). Prior to joining the company, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School. During his career, Dr. Schaber has played a significant role in raising in excess of $300 million through both public offerings and private placements, as well as over $80 million through the achievement of government grant and contract awards.

Has more than 30 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies.Prior to founding Supernus in 2005 and for more than six years, served as Board Member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Before that, was at CIMA, a drug delivery company, where last served as Executive Officer and Chairman of the Management Committee. At CIMA was also responsible for business development including licensing of CIMA’s technologies, corporate alliances and strategic planning.Prior to joining CIMA in 1995, held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in the US, Europe and the Middle East.Served as a speaker and expert panelist in several drug delivery and specialty pharma conferences, and has been interviewed by leading industry publications. In 1985, received MBA from the Wharton School of the University of Pennsylvania.

Joshua M. Tarnoff is a CEO at JDP Therapeutics Inc.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Avanish Vellanki is a Cofounder, CEO at Rain Therapeutics and is based in Fremont, California. He has worked as Senior VP:Investment Banking at Wedbush Securities, Biotechnology Investment Banking at Wedbush PacGrow Life Sciences, and Chief Business Officer at Aptose Biosciences Inc. Avanish works or has worked as Senior Dir:Corporate Dev at Proteolix, Analyst:Equity Research at Bear Stearns & Co., and Cofounder & Chairman of the Board at Independence Brewing Co. He studied at University of Minnesota-Twin Cities between 1999 and 2001, University of Minnesota Duluth, and Carlson School of Management between 2002 and 2004.